





PEDIATRIC RADIATION ONCOLOGY

Sixth Edition

Louis S. Constine

Nancy J. Tarbell

Edward C. Halperin



Wolters Kluwer

Table of Contents

- [1. Pediatric Radiation Oncology](#)
 - [1. Cover](#)
 - [2. Title Page](#)
 - [3. Copyright Information](#)
 - [4. Dedication](#)
 - [5. Contributors](#)
 - [6. Preface](#)
 - [7. Acknowledgments](#)
- [2. Chapter 1: The Cancer Problem in Children](#)
 - [1. Chapter 1 Introduction](#)
 - [1. Table 1.1: The Five Leading Causes of Death in the United States in 2011 for 1- to 19-Year-Olds](#)
 - [2. Relative Frequency of the Various Types of Childhood Cancer](#)
 - [1. Table 1.2: The Five Most Common Forms of Cancer in Adults in the United States Compared with the Five Most Common Forms of Cancer in Children](#)
 - [2. Table 1.3: The Incidence Rates of Cancer in the United States for 0- to 19-Year-Olds Expressed as a Percentage of the Total Number of Cancer Cases in This Age Group, 2006–2010](#)
 - [3. Table 1.4: The Most Common Causes of Pediatric Cancer Death in the United States, 2007–2011, by Primary Cancer Site for Ages 0–19](#)
 - [3. Trends in Childhood Cancer Mortality Rates](#)
 - [1. Table 1.5: Trends in 5-Year Relative Survival Rates for Children with Cancer \(0–14 Years of Age\) in the United States at the Approximate Midpoint of the Last Four Decades](#)
 - [4. Funding of Pediatric Cancer Research](#)
 - [1. Table 1.6: Percentage of Total Dollars Spent by Scientific Area in Pediatric Cancer Research by the United States National Cancer Institute for Fiscal Year 2013](#)
 - [2. Table 1.7: The Yearly Investment of the United States National Cancer Institute in Pediatric Cancer Research](#)
 - [5. Is the Incidence of Childhood Cancer Increasing?](#)
 - [6. What Does Cure Mean in Pediatric Oncology?](#)

7. [The Growing Population of Childhood Cancer Survivors](#)
 1. [Exhibit 22](#)
 2. [Exhibit 23](#)
 3. [Exhibit 24](#)
 4. [Table 1.8: Marriage, Employment, and Health Insurance in Adult Survivors of Childhood Cancer: A Survey of 1437 Survivors >18 Years of Age and >10 Years Postdiagnosis Treated at St. Jude Children's Research Hospital](#)
8. [Site of Care and the Pediatric Cancer Team](#)
 1. [Table 1.9: Requirements for a Pediatric Cancer Center](#)
9. [Postgraduate Training in Pediatric Radiation Oncology](#)
10. [The Problem of Evil and Childhood Cancer](#)
11. [Common Responses to the Problem of Evil](#)
12. [References](#)
3. [Chapter 2: Leukemias in Children](#)
 1. [Chapter 2 Introduction](#)
 1. [Figure 2.1](#)
 2. [Acute Lymphoblastic Leukemia](#)
 1. [Biology](#)
 2. [Clinical Presentation](#)
 3. [Staging: Risk Categories for ALL](#)
 4. [Staging: CNS Involvement in ALL](#)
 5. [Treatment: Chemotherapy](#)
 6. [Treatment: CNS Preventive Therapy](#)
 1. [Evolution of CNS Preventive Therapy in ALL](#)
 2. [Current Recommendations for Preventive CNS Therapy](#)
 7. [Radiotherapeutic Management](#)
 1. [Volume](#)
 2. [Dosage](#)
 8. [Treatment of Established CNS Leukemia](#)
 1. [CNS Leukemia at Diagnosis](#)
 2. [Radiotherapeutic Management](#)
 3. [CNS Relapse](#)
 4. [Volume and Dose](#)
 9. [Treatment of Other Extramedullary Sites](#)
 1. [Testicular Leukemia](#)
 10. [Radiotherapeutic Management](#)
 1. [Other Sites of Extramedullary Disease](#)

11. [Figure 2.2](#)
 12. [Figure 2.3](#)
 13. [Figure 2.4](#)
 14. [Figure 2.5](#)
 15. [Table 2.1: Indications for Preventive Cranial Irradiation \(pCrI\)—Contemporary Studies \(2009\)](#)
3. [Acute Myelogenous Leukemia](#)
 1. [Extramedullary Disease](#)
 2. [CNS Disease: Radiation Therapy](#)
 3. [Hematopoietic Stem Cell Transplantation \(HSCT\)](#)
 4. [HSCT in Children and Adolescents](#)
 1. [Acute Myeloblastic Leukemia](#)
 2. [Acute Lymphoblastic Leukemia](#)
 3. [Other Hematologic Diseases](#)
 5. [Radiotherapeutic Management](#)
 1. [Volume](#)
 2. [Dosage \(Hematologic Malignancies\)](#)
 6. [Figure 2.6](#)
 4. [References](#)
4. [Chapter 3: Supratentorial Brain Tumors](#)
 1. [Chapter 3 Introduction](#)
 1. [Table 3.1: Histopathologic Classification of CNS Tumors —WHO Classification 2007](#)
 2. [Figure 3.1](#)
 2. [Etiology](#)
 1. [Table 3.2: Genetic Syndromes Related to Pediatric CNS Tumors](#)
 3. [Clinical Presentation](#)
 4. [Low-Grade Supratentorial Astrocytomas](#)
 1. [Therapy](#)
 1. [Surgery](#)
 2. [Radiation Therapy](#)
 3. [Chemotherapy](#)
 2. [Radiotherapeutic Management](#)
 1. [Volume](#)
 2. [Dosage](#)
 3. [Technique](#)
 3. [Results](#)
 4. [Figure 3.2](#)
 5. [Figure 3.3](#)
 6. [Figure 3.4](#)

7. [Figure 3.5](#)
8. [Figure 3.6](#)
5. [Optic Pathway Tumors](#)
 1. [Therapy](#)
 1. [Surgery](#)
 2. [Radiation Therapy](#)
 3. [Chemotherapy](#)
 2. [Radiotherapeutic Management](#)
 1. [Volume and Technique](#)
 2. [Dosage](#)
6. [Oligodendroglioma](#)
7. [Ganglioglioma](#)
8. [Rare Low-Grade Neoplasms](#)
9. [Malignant Gliomas](#)
 1. [Therapy](#)
 1. [Surgery](#)
10. [Radiation Therapy](#)
 1. [Chemotherapy](#)
 2. [Radiotherapeutic Management](#)
 1. [Volume and Technique](#)
 2. [Dosage](#)
 3. [Results](#)
 4. [Figure 3.7](#)
11. [Embryonal CNS Tumors \(Primitive Neuroectodermal Tumors or Spnet and Pineoblastoma\)](#)
 1. [Therapy](#)
 2. [Radiotherapeutic Management](#)
 1. [Volume and Technique](#)
 2. [Dosage](#)
 3. [Figure 3.8](#)
12. [Craniopharyngioma](#)
 1. [Therapy](#)
 2. [Radiotherapeutic Management](#)
 1. [Volume and Technique](#)
 3. [Dosage](#)
 4. [Results](#)
 5. [Figure 3.9](#)
 6. [Figure 3.10](#)
 7. [Table 3.3: Craniopharyngioma—Outcome in Children](#)
13. [Intracranial Germ Cell Tumors](#)
 1. [Therapy](#)

1. [Surgery](#)
 2. [Radiation Therapy](#)
 3. [Chemotherapy](#)
 4. [Radiotherapy Management](#)
 1. [Volume and Technique](#)
 2. [Dosage](#)
 5. [Results](#)
 6. [Figure 3.11](#)
 7. [Table 3.4: Pineal Region Tumors—Relative Incidence](#)
 8. [Table 3.5: Intracranial Germinoma—Outcome](#)
 9. [Figure 3.12](#)
 10. [Figure 3.13](#)
14. [References](#)
5. [Chapter 4: Tumors of the Posterior Fossa and the Spinal Canal](#)
 1. [Chapter 4 Introduction](#)
 2. [Medulloblastoma](#)
 1. [Therapy](#)
 1. [Surgery](#)
 2. [Radiation Therapy](#)
 3. [Chemotherapy](#)
 2. [Radiotherapeutic Management](#)
 1. [Volume](#)
 2. [Dosage](#)
 3. [Technique](#)
 4. [Delivery](#)
 3. [Results](#)
 4. [Figure 4.1](#)
 5. [Table 4.1: Chang Staging for Medulloblastoma](#)
 6. [Table 4.2: Medulloblastoma—Results of Postoperative Radiation Therapy \(No Chemotherapy\)](#)
 7. [Table 4.3: Selected Major Medulloblastomas Studies Reporting Outcome with Postoperative Irradiation Combined with Chemotherapy](#)
 8. [Table 4.4: Medulloblastoma—Radiation Therapy \(Data Reporting Reduced Tumor/Target Volume Techniques\)](#)
 9. [Figure 4.2](#)
 10. [Figure 4.3](#)
 11. [Figure 4.4](#)
 12. [Figure 4.5](#)
 13. [Figure 4.6](#)
 14. [Figure 4.7](#)

3. [Embryonal and Malignant Glial Tumors in Infants and Young Children](#)
 1. [Therapy](#)
 1. [Surgery](#)
 2. [Radiation Therapy](#)
 3. [Chemotherapy](#)
 2. [Radiotherapeutic Management](#)
 1. [Volume and Technique](#)
 2. [Dosage](#)
 3. [Results](#)
 4. [Table 4.5: Malignant Infant Brain Tumors—Outcome in Selected Prospective Primary Management Trials](#)
4. [Ependymomas \(Infants, Children, and Adolescents\)](#)
 1. [Therapy](#)
 1. [Surgery](#)
 2. [Radiation Therapy](#)
 3. [Chemotherapy](#)
 2. [Radiotherapeutic Management](#)
 1. [Volume](#)
 2. [Dosage](#)
 3. [Technique](#)
 3. [Figure 4.8](#)
 4. [Table 4.6: Molecular Subgroups of Ependymoma](#)
 5. [Table 4.7: Ependymoma—Outcome Following Surgery and Irradiation](#)
 6. [Figure 4.9](#)
5. [Brainstem Glioma](#)
 1. [Therapy](#)
 1. [Surgery](#)
 2. [Radiation Therapy](#)
 3. [Chemotherapy](#)
 2. [Radiotherapeutic Management](#)
 1. [Volume](#)
 2. [Dosage](#)
 3. [Technique](#)
 3. [Results](#)
 4. [Figure 4.10](#)
 5. [Figure 4.11](#)
 6. [Figure 4.12](#)
 7. [Figure 4.13](#)
 8. [Figure 4.14](#)

6. [Cerebellar Astrocytomas](#)
 1. [Therapy](#)
 1. [Surgery](#)
 2. [Radiation Therapy](#)
 3. [Chemotherapy](#)
 2. [Radiotherapeutic Management](#)
 3. [Results](#)
 7. [Spinal Cord Neoplasms](#)
 1. [Therapy](#)
 1. [Surgery](#)
 2. [Chemotherapy](#)
 3. [Radiation Therapy](#)
 2. [Radiotherapeutic Management](#)
 1. [Volume](#)
 2. [Dosage](#)
 3. [Technique](#)
 3. [Results](#)
 4. [Figure 4.15](#)
 5. [Figure 4.16](#)
 8. [References](#)
6. [Chapter 5: Retinoblastoma](#)
 1. [Incidence](#)
 2. [Genetics](#)
 3. [Clinical Assessment](#)
 1. [Figure 5.1](#)
 2. [Figure 5.2](#)
 3. [Figure 5.3](#)
 4. [Table 5.1: The Reese–Ellsworth System of Classifying Retinoblastoma](#)
 5. [Table 5.2: International Classification System for Intraocular Retinoblastoma \(Children’s Oncology Group Version\)](#)
 4. [Treatment of Intraocular Retinoblastoma](#)
 1. [Enucleation](#)
 2. [Focal Therapy](#)
 3. [Laser](#)
 4. [Cryotherapy](#)
 5. [Radioactive Plaque Application](#)
 6. [External Beam Radiotherapy](#)
 7. [Figure 5.4](#)
 8. [Figure 5.5](#)

9. [Figure 5.6](#)
 10. [Table 5.3: Eye Preservation Following External Beam Irradiation: Selected Series Reese–Ellsworth Group](#)
 11. [Figure 5.7](#)
 5. [Chemotherapy for Intraocular Disease](#)
 1. [Intravenous Chemotherapy](#)
 2. [Ophthalmic Artery Chemosurgery](#)
 3. [Periocular Chemotherapy](#)
 4. [Intravitreal Chemotherapy](#)
 5. [Figure 5.8](#)
 6. [Extraocular Retinoblastoma](#)
 1. [Table 5.4: International Retinoblastoma Staging System](#)
 7. [Treatment due to High-Risk Enucleation Pathology](#)
 8. [Treatment of Overt Extraocular Disease](#)
 1. [Regional Extraocular Disease](#)
 2. [Stage 4a Disease](#)
 3. [CNS Retinoblastoma: Stage 4b and Trilateral Disease](#)
 9. [Palliation of Metastases](#)
 10. [Late Effects](#)
 1. [Secondary Nonocular Tumors](#)
 2. [Cataracts](#)
 3. [Orbital Development](#)
 4. [Ocular Surface Dryness](#)
 11. [References](#)
7. [Chapter 6: Neuroblastoma](#)
1. [Neuroblastoma](#)
 2. [Epidemiology and Screening](#)
 1. [Figure 6.1](#)
 2. [Figure 6.2](#)
 3. [Biology](#)
 1. [Table 6.1: Genetic Aberrations in Neuroblastoma That Are Found at Diagnosis](#)
 4. [Pathology](#)
 1. [Figure 6.3](#)
 2. [Figure 6.4](#)
 3. [Table 6.2: International Neuroblastoma Pathology Committee System](#)
 5. [Clinical Presentation and Evaluation](#)
 1. [Table 6.3: Clinical Evaluation of Neuroblastoma \(Minimum Recommended Studies to Determine the Extent of Disease\)](#)

2. [Figure 6.5](#)
6. [Staging and Prognostic Factors](#)
 1. [Staging](#)
 2. [Response Criteria](#)
 3. [Prognostic Factors](#)
 1. [Clinical](#)
 2. [Biologic](#)
 4. [Table 6.4: International Neuroblastoma Staging System](#)
 5. [Table 6.5: International Neuroblastoma Risk Group \(INRG\) Staging System](#)
 6. [Table 6.6: International Neuroblastoma Response Criteria](#)
 7. [Figure 6.6](#)
 8. [Table 6.7: International Neuroblastoma Risk Group Working Committee Modified Response Criteria](#)
 9. [Figure 6.7](#)
 10. [Table 6.8: Children's Oncology Group Neuroblastoma Risk Groups for Treatment](#)
 11. [Table 6.9: INRG Risk Classification](#)
7. [Selection of Therapy](#)
 1. [Chemotherapy](#)
 1. [Myeloablative Therapy with Hematopoietic Stem Cell Support](#)
 2. [Table 6.10: Induction Regimens for High-Risk Neuroblastoma Since 1985 \(More Than 50 Patients\)](#)
 3. [Table 6.11: EFS for High-Risk Neuroblastoma in First Remission Using Myeloablative Therapy and Hematopoietic Cell Transplant for Studies of More than 20 Patients](#)
 4. [Figure 6.8](#)
8. [Therapy for Minimal Residual Disease](#)
 1. [Figure 6.9](#)
9. [Surgery](#)
10. [Radiation Therapy](#)
 1. [Low-Risk Disease](#)
 2. [Stage 4S and Hepatomegaly](#)
 3. [Intermediate-Risk Disease](#)
 4. [High-Risk Disease](#)
 5. [CNS Metastases](#)
 6. [Metastatic Disease Treated with Palliative Intent](#)
 7. [Table 6.12: Effect of Radiation in Local Control of Advanced \(INSS 3 and 4\) Neuroblastoma](#)

11. [Adolescent and Adult Neuroblastoma](#)
12. [Radiotherapeutic Management](#)
 1. [Volume](#)
 2. [Dose](#)
 3. [Figure 6.10](#)
13. [Techniques of Radiation](#)
 1. [Figure 6.11](#)
 2. [Figure 6.12](#)
14. [Intraoperative Radiation Therapy](#)
 1. [Table 6.13: Intraoperative Radiotherapy for Neuroblastoma](#)
15. [Complications](#)
16. [Targeted Radionuclides](#)
17. [Molecularly Targeted Agents and Radiosensitizers](#)
18. [Future Investigations](#)
19. [References](#)
8. [Chapter 7: Hodgkin Lymphoma](#)
 1. [Chapter 7 Introduction](#)
 2. [Biology](#)
 1. [Figure 7.1](#)
 3. [Epidemiology](#)
 4. [Clinical Presentation](#)
 1. [Table 7.1: Ann Arbor Staging System with Cotswold Modifications for Hodgkin Lymphoma](#)
 5. [Pathologic Classification](#)
 1. [Figure 7.2](#)
 2. [Table 7.2: WHO Classification of Hodgkin Lymphoma](#)
 6. [Staging](#)
 1. [Table 7.3: Demographic and Clinical Characteristics at Presentation of Pediatric Hodgkin Lymphoma](#)
 7. [Diagnostic Evaluation](#)
 1. [Figure 7.3](#)
 8. [Prognostic Factors](#)
 9. [Selection of Therapy](#)
 10. [Evolution of Combination Chemotherapy](#)
 11. [Risk and Response-Adapted Therapy](#)
 1. [Treatment of Early-Stage Disease](#)
 2. [Treatment of Advanced and Unfavorable Disease](#)
 3. [Figure 7.4](#)
 4. [Figure 7.5](#)
 5. [Table 7.4: Summary of Treatment Results for Pediatric](#)

Hodgkin Lymphoma Trials

12. Refractory and Relapsed Disease
13. Targeted Therapies
14. Radiotherapeutic Management
15. Volume Considerations
 1. Involved-Site Radiotherapy (ISRT)
 2. Involved-Node Radiotherapy
 3. PET/CT Radiation Planning
 4. Figure 7.6
 5. Table 7.5: Involved Site Radiation Therapy (ISRT) Guidelines
 6. Figure 7.7
 7. Figure 7.8
16. Conformal Radiation Planning
 1. Figure 7.9
 2. Figure 7.10
17. Dosage Considerations
18. Sequence of Therapy
19. Results
 1. Figure 7.11
20. Complications
 1. Acute Side Effects
 2. Long-Term Side Effects
21. Future Investigations
22. References
9. Chapter 8: Non-Hodgkin Lymphoma
 1. Chapter 8 Introduction
 1. Figure 8.1
 2. Epidemiology and Etiology
 3. Clinical Presentation
 1. Table 8.1: Clinical and Biologic Features of NHL in Children
 4. Evaluation
 5. Staging and Classification
 1. Table 8.2: Murphy and St. Jude Children's Research Hospital Staging System for Childhood NHL
 2. Table 8.3: Clinical Staging of B-Cell Lymphomas
 6. Prognostic Factors
 7. Selection of Therapy
 1. Chemotherapy
 2. Table 8.4: Low-Stage/Low-Risk Patients

3. [Table 8.5: Advanced-Stage/High-Risk Patients](#)
 8. [Radiotherapeutic Management](#)
 9. [Surgical Management](#)
 10. [Results of Therapy](#)
 11. [References](#)
10. [Chapter 9: Ewing Sarcoma](#)
 1. [Chapter 9 Introduction](#)
 1. [Figure 9.1](#)
 2. [Pathology](#)
 3. [Clinical Presentation](#)
 1. [Table 9.1: Clinical Evaluation of the Patient with Ewing Sarcoma](#)
 2. [Figure 9.2](#)
 3. [Figure 9.3](#)
 4. [Table 9.2: Prognostic Factors in Ewing Sarcoma](#)
 4. [Selection of Treatment](#)
 1. [Local Control](#)
 2. [Surgery](#)
 3. [Chemotherapy](#)
 4. [Radiotherapeutic Management](#)
 1. [Volume](#)
 2. [Dosage](#)
 3. [Technique](#)
 5. [Radiation Therapy for Metastatic Disease](#)
 6. [Total-Body Irradiation and Stem Cell Transplantation](#)
 7. [Table 9.3: National Cancer Institute Protocol INT-0091 \(Children's Cancer Group Study 7881 and Pediatric Oncology Group Study 8850\)](#)
 8. [Figure 9.4](#)
 9. [Table 9.4: Influence of Chemotherapy on Local Control of Ewing Sarcoma in CCG-7881 and POG-8850](#)
 10. [Figure 9.5](#)
 5. [Cure Rates and Side Effects of Treatment](#)
 1. [Table 9.5: Second Malignancies in Patients Treated in the German Cooperative Ewing Sarcoma Studies CESS-81 and CESS-86](#)
 6. [References](#)
 11. [Chapter 10: Osteosarcoma, Chordoma, and Chondrosarcoma](#)
 1. [Chapter 10 Introduction](#)
 1. [Figure 10.1](#)
 2. [Figure 10.2](#)

2. [Signs, Symptoms, Evaluation, and Staging](#)
 1. [Figure 10.3](#)
 2. [Figure 10.4](#)
 3. [Table 10.1: A System for Osteosarcoma Subclassification by Histology and Origin](#)
 4. [Figure 10.5](#)
 5. [Table 10.2: The Enneking Staging System for Osteosarcoma](#)
 6. [Table 10.3: Influence of the Histologic Response to Neoadjuvant Chemotherapy on Survival in Osteosarcoma](#)
3. [Selection of Therapy](#)
 1. [Surgery](#)
 1. [Local Disease](#)
 2. [Metastatic Disease](#)
 2. [Radiation Therapy](#)
 1. [Prebiopsy](#)
 3. [Primary and Preoperative Treatment](#)
 1. [The Cade Technique](#)
 2. [Modern Series of Primary Photon Radiation Therapy](#)
 4. [Maxilla and Mandible](#)
 5. [Lung](#)
 6. [The Role of Adjuvant Whole-Lung Irradiation \(WLI\) in Osteosarcoma in Nonrandomized Studies](#)
 1. [Evidence from Randomized Studies](#)
 2. [WLI for Advanced Osteosarcoma](#)
 7. [Extracorporeal Irradiation \(ECI\)](#)
 8. [Chemotherapy](#)
 9. [Table 10.4: Local Recurrence Rates for Osteosarcoma as a Function of the Extent of Surgery](#)
 10. [Table 10.5: Factors Predicting Event-Free Survival in Patients with Primary Metastatic Osteosarcoma in the German-Swiss-Austrian Cooperative Osteosarcoma Study Group Clinical Trials](#)
 11. [Figure 10.6](#)
 12. [Table 10.6: The Cade Technique: Management of Osteosarcoma with Primary Irradiation or Primary Irradiation and Selected Delayed Amputation \(Excluding Parosteal Tumors\)](#)
 13. [Table 10.7: Significant Recent Cooperative Group Trials](#)

[Addressing the Management of Localized Osteosarcoma](#)

14. [Table 10.8: Prophylactic Lung Irradiation in the Treatment of Osteogenic Sarcoma](#)
15. [Figure 10.7](#)
16. [Figure 10.8](#)
4. [Radiotherapeutic Technique](#)
 1. [Dosage](#)
 2. [Volume](#)
 3. [Technique](#)
 4. [Neutron Therapy](#)
 5. [Charged Particle Therapy](#)
 6. [Intraoperative Radiation Therapy \(IORT\)](#)
 7. [Radioisotope Therapy](#)
 8. [Palliation](#)
 9. [Chordoma and Chondrosarcoma](#)
 1. [Treatment](#)
 10. [Table 10.9: Literature Review of the Local Control Rates for Osteosarcomas after Neutron Therapy](#)
 11. [Figure 10.9](#)
 12. [Figure 10.10](#)
 13. [Figure 10.11](#)
5. [References](#)
12. [Chapter 11: Rhabdomyosarcoma](#)
 1. [Chapter 11 Introduction](#)
 1. [Figure 11.1](#)
 2. [Epidemiology](#)
 1. [Figure 11.2](#)
 3. [Biology](#)
 1. [Cytogenetics](#)
 2. [Cell Cycle Control](#)
 3. [Proto-oncogenes](#)
 4. [Tumor Suppressor Genes](#)
 4. [Clinical Presentation](#)
 1. [Diagnostic Evaluation](#)
 2. [Prognostic Features](#)
 1. [Histology](#)
 2. [Favorable: Embryonal, Botryoid, and Spindle Cell Variants](#)
 3. [Unfavorable: Alveolar](#)
 4. [Stage](#)
 5. [Group](#)

6. [Primary Site](#)
7. [Other Factors](#)
3. [Table 11.1: International Classification of Rhabdomyosarcoma](#)
4. [Table 11.2: Tumor, Node, Metastasis Pretreatment Staging Classification](#)
5. [Table 11.3: The IRS Grouping System](#)
6. [Figure 11.3](#)
7. [Figure 11.4](#)
8. [Table 11.4: Lymph Node Metastasis by Primary Site for 592 Patients with Visibly Resected Disease from IRS-I and IRS-II](#)
5. [General Principles of Therapy](#)
 1. [Surgery](#)
 2. [Chemotherapy](#)
 3. [Radiation Therapy](#)
 4. [Figure 11.5](#)
 5. [Table 11.5: Design and Results of IRS-I, 1972–1978 \(686 Patients\)](#)
 6. [Table 11.6: Design and Results of IRS-II, 1978–1984 \(1003 Patients\)](#)
 7. [Table 11.7: Therapy and Outcomes According to Specific Patient Subgroups in IRS-III, 1984–1991 \(1032 Patients\)](#)
 8. [Table 11.8: Outcome for Patient with Group II Tumors According to Histology, Primary Site, and IRS Study](#)
 9. [Table 11.9: Estimated Cumulative Incidence at 5 Years of Local, Regional, and Distant Failure by Primary Site and Therapy for Patients Who Received Their Randomized Therapy on IRS-IV](#)
6. [Specific Sites](#)
 1. [Bladder and Prostate Rhabdomyosarcoma](#)
 2. [Paratesticular](#)
 3. [Vagina and Vulva](#)
 4. [Uterus and Cervix](#)
 5. [Extremity](#)
 6. [Parameningeal](#)
 7. [Orbit](#)
 8. [Other Head and Neck Sites](#)
 9. [Trunk](#)
 10. [Retroperitoneal](#)

11. [Perineal](#)
12. [Hepatobiliary Tree](#)
13. [Metastatic Disease](#)
14. [Figure 11.6](#)
15. [Figure 11.7](#)
16. [Figure 11.8](#)
17. [Figure 11.9](#)
18. [Figure 11.10](#)
19. [Figure 11.11](#)
20. [Figure 11.12](#)
21. [Figure 11.13](#)
7. [Recurrent Disease](#)
8. [Future Directions](#)
9. [References](#)
13. [Chapter 12: Soft Tissue Sarcomas Other Than Rhabdomyosarcoma; Desmoid Tumor](#)
 1. [Chapter 12 Introduction](#)
 1. [Table 12.1: Common Cytogenetic Changes in Nonrhabdomyosarcoma Soft Tissue Sarcomas](#)
 2. [Pathology](#)
 1. [Table 12.2: The Most Common Types of Childhood Nonrhabdomyosarcoma Soft Tissue Sarcoma in Recent Clinical Series](#)
 2. [Figure 12.1](#)
 3. [Figure 12.2](#)
 4. [Table 12.3: Cells of Origin of Nonrhabdomyosarcoma Soft Tissue Sarcoma of Childhood](#)
 5. [Exhibit 307](#)
 6. [Figure 12.3](#)
 7. [Figure 12.4](#)
 8. [Exhibit 310](#)
 9. [Exhibit 311](#)
 10. [Figure 12.5](#)
 3. [Presentation, Workup, and Staging](#)
 1. [Figure 12.6](#)
 2. [Table 12.4: The 2012 American Joint Committee on Cancer Staging System for Sarcoma of Soft Tissues](#)
 3. [Table 12.5: POG Grading System for Pediatric Nonrhabdomyosarcoma Soft Tissue Sarcomas](#)
 4. [Table 12.6: Tumor Differentiation Scores of Sarcoma in the French Federation of Cancer Centers System of](#)

[Grading Soft Tissue Sarcomas](#)

5. [Table 12.7: French Federation of Cancer Centres System of Grading Soft Tissue Sarcomas](#)
4. [Selection of Therapy](#)
 1. [Surgery](#)
 2. [Radiotherapy](#)
 3. [Chemotherapy](#)
 1. [Cooperative Group Studies of Chemotherapy and NRSTS Exclusive of PNET, EOES, and Askin Tumor](#)
 2. [Large-Scale Studies of Adjuvant Chemotherapy in Adults with NRSTS](#)
 3. [Modern USA and European Pediatric Cooperative Group Trials for NRSTS with Selective Use of Adjuvant Therapies Based on Risk](#)
 4. [Table 12.8: POG Protocol 8653: Local Control by Surgical Margins and Radiotherapy](#)
 5. [Table 12.9: Factors Affecting Local Relapse in NRSTS in the St. Jude Children's Research Hospital Retrospective Reviews](#)
 6. [Figure 12.7](#)
 7. [Figure 12.8](#)
5. [Radiotherapeutic Management](#)
 1. [Volume](#)
 2. [Dosage](#)
 3. [Brachytherapy and Intraoperative Radiation Therapy](#)
 4. [High-Linear Energy Transfer Radiotherapy \(e.g., Neutrons\)](#)
 5. [Figure 12.9](#)
 6. [Figure 12.10](#)
 7. [Figure 12.11](#)
6. [Results](#)
7. [Desmoid Tumors](#)
 1. [Figure 12.12](#)
 2. [Table 12.10: Local Control of Desmoid Tumors with Three Forms of Therapy](#)
 3. [Figure 12.13](#)
 4. [Table 12.11: Local Control Rates in Combined Pediatric and Adult Series of Radiotherapy with or without Surgery for the Management of Desmoid Tumors](#)

8. References

14. Chapter 13: Wilms Tumor

1. History

1. Figure 13.1

2. Epidemiology

3. Molecular Biology

1. Table 13.1: Analysis for the Joint Effect of LOH at 1p and 16q for (A) Stage I/II and (B) Stage III/IV Favorable Histology Patients (29)

2. Table 13.2: COG Risk-Stratification Schema for Renal Tumor Protocols

4. Pathology

1. Mesoblastic Nephroma

2. Nodular Renal Blastemas and Nephrogenic Rests

3. Wilms Tumor

4. Rhabdoid Tumor of the Kidney

5. Clear Cell Sarcoma of the Kidney

6. Table 13.3: Classification of Pediatric Renal Tumors

7. Table 13.4: International Society of Pediatric Oncology National Wilms Tumor Study

8. Table 13.5: Children's Oncology Group Classification of Renal Tumors

9. Figure 13.2

10. Figure 13.3

11. Figure 13.4

12. Figure 13.5

5. Clinical Presentation and Workup

1. Figure 13.6

6. Staging

1. Table 13.6: Children's Oncology Group Staging of Wilms Tumor

2. Table 13.7: Staging System Used in SIOP Wilms Tumor Trial 1

7. Nwts, Siop, and the Management of Wilms Tumor

1. The NWTS and SIOP Strategies

2. The National Wilms Tumor Studies

3. Children's Oncology Group Studies

4. AREN03B2

5. AREN0321

6. AREN0532

7. AREN0533

8. [AREN0534](#)
9. [SIOP Wilms Tumor Studies](#)
10. [Table 13.8: NWTS-1 Results](#)
11. [Figure 13.7](#)
12. [Table 13.9: NWTS-2 Results](#)
13. [Figure 13.8](#)
14. [Figure 13.9](#)
15. [Table 13.10: NWTS-3 Results](#)
16. [Table 13.11: NWTS-3 Relapse Rates](#)
17. [Figure 13.10](#)
18. [Table 13.12: NWTS-4 Results](#)
19. [Table 13.13: Comparing Results: NWTS-4 and UK Children's Cancer Study Group Wilms Tumor Study 2](#)
20. [Table 13.14: Risk of Local Recurrence in NWTS-4](#)
21. [Table 13.15: COG Radiation Therapy Guidelines](#)
22. [Table 13.16: COG Chemotherapy Regimens](#)
23. [Table 13.17: Results of the Treatment of New Cases of Historically Confirmed Wilms Tumor, with More Than 2 Years of Follow-Up, As Reported by Schweisguth and Bamberger of the Institut Gustave Roussy in 1963](#)
24. [Table 13.18: SIOP 1 Wilms Tumor Treatment Protocol](#)
25. [Table 13.19: SIOP 1 Results](#)
26. [Table 13.20: SIOP 2 Wilms Tumor Treatment Protocol](#)
27. [Table 13.21: SIOP 2 Results](#)
28. [Table 13.22: SIOP 5 Wilms Tumor Treatment Protocol](#)
29. [Table 13.23: SIOP 5 Results](#)
30. [Table 13.24: Effect of Preoperative Treatment: SIOP Trial 5](#)
31. [Table 13.25: SIOP 6 Wilms Tumor Treatment Protocol](#)
32. [Table 13.26: SIOP 6 Results](#)
33. [Table 13.27: SIOP 9 Wilms Tumor Treatment Protocol](#)
34. [Table 13.28: SIOP 9: Stage IV Protocol](#)
35. [Table 13.29: SIOP 9 Results](#)
36. [Table 13.30: SIOP 93-01 Wilms Tumor Treatment: Postoperative Treatment Strategies for Unilateral Wilms Tumor](#)
37. [Table 13.31: SIOP 93-01 Stage IV Protocol](#)
38. [Table 13.32: SIOP 93-01 Results](#)
39. [Table 13.33: SIOP 93-01 Results](#)
40. [Table 13.34: SIOP 2001 Postoperative Treatment Strategies for Localized Tumors](#)

41. [Table 13.35: SIOP 2001 Stage IV Postoperative Treatment](#)
42. [Table 13.36: SIOP 2001 Indications for Radiotherapy](#)
43. [Table 13.37: SIOP 2001 Radiation Therapy Dosage \(Total Dose/Dose per Fraction\)](#)
8. [Selection of Therapy](#)
 1. [Surgery](#)
 2. [Radiation Therapy](#)
 3. [Chemotherapy](#)
9. [Radiotherapeutic Management](#)
 1. [Volume](#)
 2. [Figure 13.11](#)
 3. [Figure 13.12](#)
 4. [Figure 13.13](#)
10. [Dosage for Abdominal Disease](#)
 1. [Intensity-Modulated Radiation Therapy in Wilms Tumor](#)
 2. [Bilateral Wilms Tumor](#)
 3. [Metastatic Disease](#)
 4. [Recurrent Wilms Tumor](#)
 5. [Renal Tumors in Very Young Children](#)
11. [Toxicities](#)
 1. [Hematologic Toxicity](#)
 2. [Hepatic Effects](#)
 3. [Orthopedic Effects](#)
 4. [Renal Effects](#)
 5. [Cardiac Effects](#)
 6. [Pulmonary Effects](#)
 7. [Pregnancy Outcome](#)
 8. [Treatment-Induced Neoplasms](#)
 9. [Growth Abnormalities](#)
 10. [Table 13.38: Long-Term Complications of Renal Function](#)
 11. [Table 13.39: Long-Term Complications of Cardiac Function \(99\)](#)
 12. [Table 13.40: Pregnancy Outcome](#)
 13. [Table 13.41: Predicted Deficit in Height at Age 18 Years after Flank Irradiation at Selected Ages and Dosages](#)
12. [Future Developments](#)
13. [References](#)
15. [Chapter 14: Liver Tumors in Children](#)
 1. [Chapter 14 Introduction](#)
 1. [Table 14.1: Incidence of Primary Hepatic Tumors in](#)

Childhood

2. Benign Tumors
 1. Vascular Tumors
 2. Mesenchymal Hamartoma
 3. Focal Nodular Hyperplasia and Hepatic Adenomas
3. Primary Malignant Liver Tumors
 1. Hepatoblastoma
 2. Hepatocellular Carcinoma
 3. Undifferentiated Embryonal Sarcoma of the Liver
 4. Table 14.2: Histologic Classification of Hepatoblastoma
 5. Figure 14.1
 6. Figure 14.2
 7. Figure 14.3
4. Diagnosis
 1. Genomic Abnormality
 2. Figure 14.4
5. Staging
 1. Table 14.3: Staging System of Hepatoblastoma by the Children's Oncology Group
 2. Figure 14.5
6. Selection of Therapy
 1. Surgery
 2. Chemotherapy
 3. Radiation Therapy
 4. Table 14.4: Hepatoblastoma Staging and Risk Stratification
 5. Table 14.5: Multicenter Studies in Hepatoblastoma—Comparison of Results
 6. Table 14.6: Results of the Pediatric Intergroup Hepatoma Study for Hepatoblastoma (CCG-8881 and POG-8945)
 7. Table 14.7: Summary of Recent Hepatoblastoma Multicenter Trials (12,25,31,36,53,54,55,59,60,66,67,68)
 8. Figure 14.6
 9. Table 14.8: Current Chemotherapy Recommendations of the Different Study Groups (66,68,73,74,75)
7. Results and Future Directions
8. References
16. Chapter 15: Germ and Stromal Cell Tumors of the Gonads and Extragonadal Germ Cell Tumors
 1. Chapter 15 Introduction
 1. Figure 15.1

3. [Table 15.1: Biologic Characteristics of Pediatric Germ Cell Tumors](#)
3. [Table 15.2: Grading of Immature Teratomas](#)
2. [General Aspects of Clinical Presentation, Staging, and Workup](#)
 1. [Ovary](#)
 2. [Testis](#)
 3. [Extragenital](#)
 1. [Sacrococcygeal Tumor \(SCT\)](#)
 2. [Mediastinal GCT](#)
 3. [The Role of Radiotherapy](#)
 4. [Figure 15.2](#)
 5. [Table 15.3: Children's Oncology Group Surgical Guidelines for Ovarian Germ Cell Tumor in Pediatric Patients](#)
 6. [Table 15.4: Children's Oncology Group Staging for Pediatric Ovarian Germ Cell Tumors](#)
 7. [Figure 15.3](#)
 8. [Table 15.5: Children's Oncology Group Staging for Pediatric Testicular Germ Cell Tumor](#)
 9. [Figure 15.4](#)
 10. [Table 15.6: TNM Classification \(UICC 2009\)](#)
 11. [Table 15.7: Children's Oncology Group Staging for Pediatric Malignant Extragenital Germ Cell Tumors](#)
 12. [Figure 15.5](#)
3. [Results](#)
4. [References](#)
17. [Chapter 16: Endocrine, Aerodigestive Tract, and Breast Tumors](#)
 1. [Adrenocortical Carcinoma](#)
 1. [Histology](#)
 2. [Epidemiology](#)
 3. [Genetics](#)
 4. [Clinical Aspects](#)
 5. [Biology](#)
 6. [Molecular Biology](#)
 7. [Prognostic Factors](#)
 8. [Imaging](#)
 9. [Treatment](#)
 1. [Surgery](#)
 2. [Chemotherapy](#)
 3. [Radiotherapy](#)
 10. [Follow-Up](#)

11. [Results](#)
12. [Table 16.1: Constitutional Genetic Abnormalities Associated with Adrenal Cortical Tumors \(ACT\)](#)
13. [Figure 16.1](#)
2. [Pheochromocytoma and Paraganglioma](#)
 1. [Definition](#)
 2. [Histology](#)
 3. [Epidemiology](#)
 4. [Genetics](#)
 5. [Clinical Aspect](#)
 6. [Biology](#)
 7. [Imaging](#)
 8. [Treatment](#)
 9. [Results](#)
3. [Thyroid Carcinoma](#)
 1. [Histology/Epidemiology](#)
 2. [Follicular, Papillary, and Poorly Differentiated Carcinomas](#)
 1. [Risk Factors](#)
 2. [Clinical Aspects](#)
 3. [Imaging](#)
 4. [Prognostic Factor](#)
 5. [Treatment](#)
 3. [Follow-Up](#)
 4. [Results](#)
 5. [Table 16.2: Differentiated Thyroid Cancer in Children from 11 Pediatric Series](#)
4. [Radiation-Associated Thyroid Cancer in Children](#)
 1. [Cancer Survivors](#)
 2. [The Chernobyl Accident](#)
5. [Medullary Thyroid Carcinoma](#)
 1. [Clinical Aspect](#)
 2. [Genetics](#)
 3. [Treatment](#)
6. [Aerodigestive Tract](#)
 1. [Juvenile Nasopharyngeal Angiofibroma](#)
 1. [Epidemiology](#)
 2. [Histology](#)
 3. [Clinical Aspect](#)
 4. [Imaging](#)
 5. [Prognostic Factors](#)

6. [Classification](#)
 7. [Treatment](#)
2. [Nasopharyngeal Carcinoma \(NPC\)](#)
 1. [Histology](#)
 2. [Epidemiology](#)
 3. [Genetics](#)
 4. [Clinical Aspects](#)
 5. [Biology](#)
 6. [Imaging](#)
 7. [Prognostic Factors](#)
 8. [Classification](#)
 9. [Treatment](#)
 10. [Results](#)
 11. [Late Effects](#)
3. [Esthesioneuroblastoma \(or Olfactory Neuroblastoma\)](#)
 1. [Epidemiology](#)
 2. [Histology](#)
 3. [Clinical Aspect](#)
 4. [Imagery](#)
 5. [Classification](#)
 6. [Treatment](#)
 7. [Results](#)
4. [Table 16.3: Radiotherapy for Juvenile Nasopharyngeal Angiofibroma: Most Recent Studies](#)
5. [Figure 16.2](#)
6. [Table 16.4: Staging System for Carcinoma of the Nasopharynx](#)
7. [Table 16.5: Survival in Childhood Nasopharyngeal Carcinomas: Studies During the 1990s and 2000s](#)
8. [Table 16.6: Kadish Staging System](#)
9. [Table 16.7: Local Recurrence Rates in Retrospective Series of the Treatment of Esthesioneuroblastoma: Combined Adult and Pediatric Series](#)
7. [Malignancies of the Oral Cavity, Oropharynx, Hypopharynx, and Larynx](#)
 1. [Epidemiology](#)
8. [Salivary Gland Tumors](#)
 1. [Epidemiology](#)
 2. [Pathology](#)
 1. [Mucoepidermoid Carcinoma As Second Tumors](#)

3. [Clinical Aspects](#)
 4. [Treatment](#)
 9. [Infantile Subglottic Hemangiomas](#)
 1. [Treatment](#)
 10. [Esophageal Cancers](#)
 11. [Gastrointestinal Malignancies](#)
 12. [Pulmonary Neoplasm](#)
 1. [Epidemiology](#)
 2. [Pathology](#)
 3. [Clinical Presentation](#)
 1. [Pleuropulmonary Blastoma \(PPB\)](#)
 4. [Genetics](#)
 5. [Diagnosis](#)
 6. [Treatment](#)
 7. [Results](#)
 13. [Carcinoid and Mucoepidermoid Bronchial Tumors](#)
 14. [Neoplasms of the Pancreas](#)
 15. [Pancreatoblastoma](#)
 1. [Histology](#)
 2. [Diagnosis](#)
 3. [Treatment](#)
 16. [Colorectal Malignancies](#)
 17. [Breast Cancer](#)
 18. [References](#)
 18. [Chapter 17: Langerhans Cell Histiocytosis](#)
 1. [Historical Background](#)
 1. [Figure 17.1](#)
 2. [Definition, Pathogenesis, and Pathology](#)
 1. [Figure 17.2](#)
 2. [Figure 17.3](#)
 3. [Table 17.1: Immunophenotype of Langerhans Cell Histiocytosis](#)
 3. [Clinical Presentation, Diagnostic Evaluation, and Staging](#)
 1. [Table 17.2: An Overview of the Clinical Presentation of Langerhans Cell Histiocytosis in Several Recent Clinical Series](#)
 2. [Table 17.3: Sites of Bone Involvement in Langerhans Cell Histiocytosis: A Summary from the Published Literature](#)
 3. [Figure 17.4](#)
 4. [Figure 17.5](#)
 5. [Table 17.4: Treatment of Localized Langerhans Cell](#)

Histiocytosis of Bone with Intralesional Corticosteroid Injection

4. Selection of Therapy
 1. Surgery
 2. Bone Sites Not Appropriate for Surgery
 3. Direct Injection of Steroids
 4. Radiation Therapy
 5. Chemotherapy
 1. AIEOP-CNR-HX*83
 2. DAL-HX83
 3. DAL-HX90
 4. LCH 1
 5. LCH2
 6. JLSG-96
 7. LCH3
 8. Salvage Therapy
 9. Skin Therapy
 6. Liver and Bone Marrow Transplantation
 7. Table 17.5: A Treatment Algorithm for Langerhans Cell Histiocytosis
 8. Table 17.6: Results of External Beam Radiation Therapy for Langerhans Cell Histiocytosis of Bone
 9. Figure 17.6
5. Radiotherapeutic Management
 1. Dosage
 2. Volume
 3. Figure 17.7
 4. Figure 17.8
 5. Figure 17.9
6. Long-Term Sequelae of LCH and Its Treatment
7. Results
8. References
19. Chapter 18: Vascular Neoplasms and Skin Cancer
 1. Vascular Neoplasms
 1. Table 18.1: Vascular Malformations
 2. Table 18.2: Vascular Neoplasms
 2. Vasculoproliferative Tumors
 3. Vascular Malformations
 4. Basal and Squamous Cell Carcinomas
 5. Malignant Melanoma
 1. Table 18.3: Classification of the Primary Lesion in

Malignant Melanoma

- Figure 18.1
- Figure 18.2

6. References

20. Chapter 19: Late Effects of Cancer Treatment

1. Chapter 19 Introduction

- Figure 19.1
- Figure 19.2
- Figure 19.3

2. Effects of Chemotherapy and Radiotherapy on Normal Tissue

- Table 19.1: Tolerance Dosages, TD5–TD50 (Fractionated Dosage, Whole or Partial Organ)
- Table 19.2: Common Chemotherapy Late Effects

3. Influence of the Developmental Stage of the Target Organ on Its Sensitivity to Therapy

- Figure 19.4
- Table 19.3: Anatomy and Physiology: Relative Rate of Development
- Figure 19.5

4. Late Effects by Organ System

1. Central Nervous System

- Pathophysiology
- Clinical Manifestations
- Cerebrovascular Disease
- Additional Manifestations
- Psychosocial

2. Neuroendocrine

- Growth Hormone
- Clinical Manifestations
- Non–Growth Hormone Tropins

3. Thyroid

- Pathophysiology
- Hypothyroidism
- Hyperthyroidism
- Detection and Screening
- Management

4. Bone and Body Composition

- Pathophysiology
- Clinical Manifestations
- Other Skeletal Abnormalities

5. Cardiac

1. [Pericarditis](#)
2. [Cardiomyopathy](#)
3. [Valvular Disease](#)
4. [Arrhythmia](#)
5. [Coronary Artery Disease](#)
6. [Lungs](#)
 1. [Pathophysiology](#)
 2. [Clinical Manifestations](#)
 3. [Radiation and Chemotherapy Effects on the Lung](#)
7. [Ovary](#)
 1. [Pathophysiology](#)
 2. [Clinical Manifestations](#)
8. [Breast](#)
9. [Testes](#)
 1. [Pathophysiology](#)
 2. [Clinical Manifestations](#)
 3. [Reproduction and Offspring](#)
10. [Urinary System](#)
11. [Kidney](#)
 1. [Pathophysiology](#)
 2. [Clinical Manifestations](#)
12. [Urinary Bladder](#)
13. [Digestive Tract](#)
14. [Pancreas](#)
15. [Liver](#)
16. [Eye](#)
 1. [Retina](#)
 2. [Lacrimal Apparatus](#)
 3. [Lens](#)
 4. [Optic Nerve](#)
 5. [Lid](#)
 6. [Orbit](#)
17. [Hearing](#)
18. [Teeth and Salivary Glands](#)
19. [Bone Marrow](#)
20. [Figure 19.6](#)
21. [Figure 19.7](#)
22. [Table 19.4: Evaluation of Patients at Risk for Late Effects: Central Nervous System](#)
23. [Figure 19.8](#)

24. [Figure 19.9](#)
25. [Table 19.5: Evaluation of Patients at Risk for Late Effects: Neuroendocrine](#)
26. [Figure 19.10](#)
27. [Table 19.6: Evaluation of Patients at Risk for Late Effects: Thyroid](#)
28. [Figure 19.11](#)
29. [Table 19.7: Evaluation of Patients at Risk for Late Effects: Musculoskeletal](#)
30. [Figure 19.12](#)
31. [Figure 19.13](#)
32. [Figure 19.14](#)
33. [Table 19.8: Evaluation of Patients at Risk for Late Effects: Cardiac](#)
34. [Figure 19.15](#)
35. [Table 19.9: Evaluation of Patients at Risk for Late Effects: Pulmonary](#)
36. [Table 19.10: Effect of Fractionated Irradiation on Ovarian Function in Women of Reproductive Age](#)
37. [Figure 19.16](#)
38. [Table 19.11: Evaluation of Patients at Risk for Late Effects: Ovarian](#)
39. [Table 19.12: Effect of Fractionated Testicular Irradiation on Spermatogenesis and Leydig Cell Function](#)
40. [Table 19.13: Evaluation of Patients at Risk for Late Effects: Testicular](#)
41. [Figure 19.17](#)
42. [Table 19.14: Evaluation of Patients at Risk for Late Effects: Genitourinary](#)
43. [Table 19.15: Evaluation of Patients at Risk for Late Effects: Gastrointestinal](#)
44. [Figure 19.18](#)
45. [Table 19.16: Evaluation of Patients at Risk for Late Effects: Eye](#)
46. [Figure 19.19](#)
47. [Table 19.17: Evaluation of Patients at Risk for Late Effects: Ear](#)
48. [Figure 19.20](#)
49. [Table 19.18: Evaluation of Patients at Risk for Late Effects: Dental and Salivary](#)
50. [Figure 19.21](#)

51. [Table 19.19: Antineoplastic Drug Category and Agent with Their Relative Degree and Duration of Myelosuppression](#)
5. [Conclusions and Future Directions](#)
6. [References](#)
21. [Chapter 20: Second Primary Cancers](#)
 1. [Chapter 20 Introduction](#)
 2. [Second Primary Cancers: The Scope of the Problem](#)
 1. [Figure 20.1](#)
 3. [Risk Factors for Second Primary Cancers](#)
 1. [Primary Diagnosis](#)
 2. [Host-Related Risk Factors](#)
 1. [Age at Diagnosis of Primary Cancer](#)
 2. [Sex](#)
 3. [Therapy-Related Risk Factors](#)
 1. [Radiation](#)
 2. [Chemotherapeutic Agents](#)
 4. [Environmental and Lifestyle Factors](#)
 5. [Characteristics of Second Primary Cancers](#)
 1. [Alkylating Agent–Associated Acute Myeloid Leukemia and Myelodysplasia](#)
 2. [Topoisomerase II Inhibitor–Associated Acute Myeloid Leukemia](#)
 6. [Musculoskeletal Tumors](#)
 7. [Breast Cancer](#)
 8. [Thyroid Cancer](#)
 9. [Brain Tumor](#)
 10. [Other Carcinomas](#)
 11. [Lung Cancer](#)
 12. [Skin Cancer](#)
 1. [Nonmelanoma skin cancer \(NMSC\)](#)
 2. [Melanoma](#)
 13. [Bladder](#)
 14. [Renal Cell Carcinoma](#)
 15. [Salivary Gland Tumors](#)
 16. [Molecular Underpinnings of Second Primary Cancers](#)
 17. [Drug Metabolism and Disposition](#)
 18. [DNA Repair](#)
 19. [Role of Genetic Susceptibility in Therapy-Related Leukemia](#)
 1. [Drug Metabolism and Risk of t-MDS/AML](#)

2. [DNA Damage and Repair and t-MDS/AML](#)
 3. [Impact of Antimetabolite Drugs and DNA Synthesis/Repair on t-MDS/AML Risk](#)
 20. [Role of Genetic Susceptibility in Therapy-Related Solid SPCs](#)
 1. [Breast cancer](#)
 2. [Meningioma](#)
 3. [Thyroid cancer](#)
 21. [Table 20.1: Second Primary Cancers and their Relationship with Primary Cancers](#)
 22. [Figure 20.2](#)
 23. [Figure 20.3](#)
 24. [Table 20.2: Characteristics of Therapy-Related Myelodysplasia or Acute Myeloid Leukemia after Treatment with Alkylating Agents and Topoisomerase II Inhibitors](#)
 25. [Figure 20.4](#)
 26. [Table 20.3: Risk of Breast Cancer in Hodgkin Lymphoma Survivors by Age and Latency](#)
 27. [Table 20.4: Role of Genetic Susceptibility in the Development of Therapy-Related Myelodysplasia/Acute Myeloid Leukemia](#)
 28. [Table 20.5: Role of Genetic Susceptibility in the Development of Therapy-Related Solid Subsequent Malignant Neoplasms](#)
 4. [Primary Cancers Associated with Second Primary Cancers](#)
 1. [Retinoblastoma](#)
 1. [Hodgkin Lymphoma](#)
 2. [Prevention Strategies](#)
 3. [Future Directions](#)
 4. [Figure 20.5](#)
 5. [Figure 20.6](#)
 6. [Figure 20.7](#)
 5. [References](#)

22. [Chapter 21: Anesthesia for External Beam Radiotherapy](#)

 1. [Chapter 21 Introduction](#)
 2. [Behavioral Techniques to Avoid Anesthesia](#)
 3. [Frequency of Anesthesia for Pediatric Radiotherapy](#)
 1. [Table 21.1: Need for Anesthesia in Children as a Function of Age at Initiation of Irradiation](#)
 4. [Goals of Anesthesia for Radiotherapy](#)

1. [Table 21.2: Goals for Ideal Anesthesia for Outpatient Pediatric Radiation Therapy](#)
 5. [Inhaled Anesthetics](#)
 1. [Table 21.3: Inhalation Anesthetic Agents Commonly Used in Pediatric Radiation Therapy](#)
 2. [Figure 21.1](#)
 3. [Figure 21.2](#)
 4. [Figure 21.3](#)
 5. [Figure 21.4](#)
 6. [Intravenous Anesthetics](#)
 7. [Sedation or Anesthesia?](#)
 8. [Anesthesia Monitoring](#)
 1. [Figure 21.5](#)
 2. [Figure 21.6](#)
 3. [Figure 21.7](#)
 4. [Figure 21.8](#)
 9. [Anesthetic Implications of Underlying Disease](#)
 1. [Figure 21.9](#)
 10. [References](#)
23. [Chapter 22: Psychosocial Aspects of Radiotherapy for the Child and Family with Cancer](#)
 1. [Chapter 22 Introduction](#)
 2. [Cognitive Effects of Radiotherapy](#)
 1. [Effects of RT on Intelligence](#)
 2. [Effects of RT on Specific Cognitive Functions](#)
 3. [Further Factors Involved in Cognitive Functioning](#)
 4. [Table 22.1: Studies about the Effects of RT on IQ Scores](#)
 3. [Social and Behavioral Effects of RT](#)
 1. [Table 22.2: Behavioral and Social Effects of RT](#)
 4. [Children's Distress in the Course of RT](#)
 1. [Effects of RT on the Children's Quality of Life](#)
 2. [Intervention Procedures for Reducing Distress during RT](#)
 3. [Figure 22.1](#)
 5. [Interview](#)
 1. [The Views of the Children and the Parents about RT](#)
 2. [Results Based on Interviewing Parents](#)
 3. [Results Based on Interviewing the Children](#)
 4. [Some Comments Concerning the Interviews](#)
 5. [Figure 22.2](#)
 6. [Summary](#)
 7. [References](#)

24. Appendix

1. Remarks


PEDIATRIC RADIATION ONCOLOGY

Sixth Edition

Louis S. Constine

Nancy J. Tarbell

Edward C. Halperin



 Wolters Kluwer

Pediatric Radiation Oncology

SIXTH EDITION

Louis S. Constine, MD, FASTRO

The Philip Rubin Professor of Radiation Oncology and Pediatrics
Vice Chair

Department of Radiation Oncology

Director

The Judy DiMarzo Cancer Survivorship Program

James P. Wilmot Cancer Institute

University of Rochester Medical Center

Rochester, New York

Nancy J. Tarbell, MD, FASTRO

CC Wang Professor of Radiation Oncology

Department of Radiation Oncology

Massachusetts General Hospital

Dean for Academic and Clinical Affairs

Harvard Medical School

Boston, Massachusetts

Edward C. Halperin, MD, MA

Chancellor/Chief Executive Officer

Professor of Radiation Oncology, Pediatrics, and History

New York Medical College

Provost for Biomedical Affairs

Touro College and University

Valhalla, New York



Wolters Kluwer

Philadelphia • Baltimore • New York • London
Buenos Aires • Hong Kong • Sydney • Tokyo

Acquisitions Editor: Julie Goolsby

Senior Product Development Editor: Emilie Moyer

Production Product Manager: Bridgett Dougherty



Manufacturing Manager: Beth Welsh

Marketing Manager: Rachel Mante Leung

Design Coordinator: Holly McLaughlin

Production Service: S4Carlisle Publishing Services

© 2016 by Wolters Kluwer.

© 2011, 2004, 1999 by Lippincott Williams & Wilkins, a Wolters Kluwer business. © 1994, 1986 by Raven Press. All rights reserved. This book is protected by copyright. No part of this book may be reproduced or transmitted in any form or by any means, including as photocopies or scanned-in or other electronic copies, or utilized by any information storage and retrieval system without written permission from the copyright owner, except for brief quotations embodied in critical articles and reviews. Materials appearing in this book prepared by individuals as part of their official duties as U.S. government employees are not covered by the above-mentioned copyright. To request permission, please contact Wolters Kluwer at Two Commerce Square, 2001 Market Street, Philadelphia, PA 19103, via email at permissions@lww.com , or via our website at lww.com  (products and services).

10 9 8 7 6 5 4 3 2 1

Printed in China

Library of Congress Cataloging-in-Publication Data

Names: Constine, Louis S., editor. | Tarbell, Nancy J., 1951- editor. | Halperin, Edward C., editor.

Title: Pediatric radiation oncology / editors, Louis S. Constine, Nancy J. Tarbell, Edward C. Halperin.

Description: Sixth edition. | Philadelphia, PA : Wolters Kluwer, [2016] | Includes bibliographical references and index.

Identifiers: LCCN 2016020698 | ISBN 9781496342867

Subjects: | MESH: Neoplasms—radiotherapy | Child

Classification: LCC RC281.C4 | NLM QZ 275 | DDC 618.92/9920642—dc23 LC reco

<https://lccn.loc.gov/2016020698> 

This work is provided “as is,” and the publisher disclaims any and all warranties, express or implied, including any warranties as to accuracy, comprehensiveness, or currency of the content of this work.

This work is no substitute for individual patient assessment based upon health care professionals’ examination of each patient and consideration of, among other things, age, weight, gender, current or prior medical conditions, medication history, laboratory data, and other factors unique to the patient. The publisher does not provide medical advice or guidance, and this work is merely a reference tool. Health care professionals, and not the publisher, are solely responsible for the use of this work, including all medical judgments, and for any resulting diagnosis and treatments.

Given continuous, rapid advances in medical science and health information, independent professional verification of medical diagnoses, indications, appropriate pharmaceutical selections and dosages, and treatment options should be made and health care professionals should consult a variety of sources. When prescribing medication, health care professionals are advised to consult the product information sheet (the manufacturer's package insert) accompanying each drug to verify, among other things, conditions of use, warnings, and side effects and identify any changes in dosage schedule or contraindications, particularly if the medication to be administered is new, infrequently used, or has a narrow therapeutic range. To the maximum extent permitted under applicable law, no responsibility is assumed by the publisher for any injury and/or damage to persons or property, as a matter of products liability, negligence law, or otherwise, or from any reference to or use by any person of this work.

Dedication

This book is dedicated both to our own children and to all those children diagnosed with cancer. These children have taught us about life, bravery, pain, openness, innocence, resilience, as well as clinical pediatric radiation oncology. To them we are forever grateful. Through our patients we have learned to more profoundly appreciate our own families. We pause to recognize those children who succumbed to cancer, and to feel gratitude for those fortunate to have survived while retaining a childlike enthusiasm for living despite the burden of malignancy. We hope that the sixth edition of *Pediatric Radiation Oncology* will serve as some small reciprocation for what our patients have given to us.

*Louis S. Constine
Nancy J. Tarbell
Edward C. Halperin*

Contributors

David H. Abramson, MD, FACS

Chief

Ophthalmic Oncology Service

Memorial Sloan Kettering Cancer Center

Professor

Department of Ophthalmology

Weill-Cornell Medical Center

New York, New York

James E. Bates, MD

Resident

Department of Radiation Oncology

University of Florida

Gainesville, Florida

Myriam Weyl Ben Arush, MD

Professor

Department of Pediatrics

Professor

Division of Pediatric Hematology Oncology

Rappaport Faculty of Medicine

Technion - Israel Institute of Technology

Chief

Division of Pediatric Hematology and Oncology

The Ruth Rappaport Children's Hospital

Rambam Health Care Campus

Haifa, Israel

Smita Bhatia, MD, MPH

Professor
Department of Pediatrics
Director
Institute of Cancer Outcomes and Survivorship
School of Medicine
University of Alabama
Birmingham, Alabama

Steve E. Braunstein, MD, PhD

Assistant Professor
Department of Radiation Oncology
University of California
San Francisco, California

Christian Carrie, MD

Chief
Department of Radiotherapy
Centre Léon Bérard
Lyon, France

Bow-Wen Chen, MD

Senior Pediatrician
Division of Pediatric Hematology and Oncology
Medical Director
Hematopoietic Stem Cell Research Laboratory
Koo Foundation Sun Ya-Sen Cancer Center
Taipei, Taiwan

Skye H. Cheng, MD

Chief
Department of Radiation Oncology
Director
Clinical Research Office
Deputy Chief
Department of Research
Koo Foundation Sun Yat-Sen Cancer Center
Taipei, Taiwan

Line Claude, MD

Assistant Head
Department of Radiation Oncology
Centre Léon Bérard
Ly on, France

Louis S. Constine, MD, FASTRO

The Philip Rubin Professor of Radiation Oncology and Pediatrics
Vice Chair
Department of Radiation Oncology
Director
The Judy DiMarzo Cancer Survivorship Program
James P. Wilmot Cancer Institute
University of Rochester Medical Center
Rochester, New York

Sughosh Dhakal, MD

Assistant Professor
Medical Director
Department of Radiation Oncology
James P. Wilmot Cancer Institute/Strong Memorial Hospital
University of Rochester Medical Center
Rochester, New York

Xavier Druet

Internship Department of Radiotherapy
Institut du cancer de Montpellier(ICM)
Montpellier, France

Ira J. Dunkel, MD

Associate Attending Physician
Department of Pediatrics
Memorial Sloan Kettering Cancer Center
New York, New York

Bree R. Eaton, MD

Assistant Professor
Department of Radiation Oncology

Winship Cancer Institute
Emory University
Atlanta, Georgia

Natia Esiashvili, MD

Associate Professor
Department of Radiation Oncology
Winship Cancer Institute
Woodruff Health Sciences Center
Emory University
Atlanta, Georgia

Marla B. Ferschl, MD

Associate Professor
Department of Anesthesia and Perioperative Care
Division of Pediatric Anesthesia
Program Director
Pediatric Anesthesia Fellowship Program
University of California
San Francisco, California

Jasmine H. Francis, MD, FACS

Assistant Attending Physician
Ophthalmic Oncology Service
Department of Surgery
Memorial Sloan Kettering Cancer Center
New York, New York

Heather J. Frederick, MD, MHSc

Assistant Professor
Department of Anesthesiology
Duke University Medical Center
Durham, North Carolina

Debra L. Friedman, MD

Associate Professor of Pediatrics
E. Bronson Ingram Chair in Pediatric Oncology
Department of Pediatrics

Vanderbilt-Ingram Cancer Center
Cancer Control and Prevention Program
Director
Division of Hematology -Oncology
Vanderbilt University
Nashville, Tennessee

Alison M. Friedmann, MD, MSc

Assistant Professor
Department of Pediatrics
Division of Pediatric Hematology and Oncology
Harvard Medical School
Massachusetts General Hospital
Boston, Massachusetts

Hana Golan, MD

Department of Pediatric Hematology and Oncology
The Edmond and Lily Safra Children's Hospital
Sheba Medical Center
Tel Hashomer, Israel

Daphne Haas-Kogan, MD

Professor and Chair
Department of Radiation Oncology
Brigham and Women's Hospital
Dana-Farber Cancer Institute
Boston Children's Hospital
Harvard Medical School
Boston, Massachusetts

Edward C. Halperin, MD, MA

Chancellor/Chief Executive Officer
Professor of Radiation Oncology, Pediatrics, and History
New York Medical College
Provost for Biomedical Affairs
Touro College and University
Valhalla, New York

Andrew T. Huang, MD

Professor

Department of Medicine

Duke University Medical School

Durham, North Carolina

President and CEO

Koo Foundation Sun Yat-Sen Cancer Center

Taipei, Taiwan

Mary S. Huang, MD

Assistant Professor

Department of Pediatrics

Pediatric Hematology and Oncology Unit

Massachusetts General Hospital for Children

Boston, Massachusetts

John A. Kalapurakal, MD, FACR

Professor and Vice Chair

Department of Radiation Oncology

Northwestern University Feinberg School of Medicine

Chicago, Illinois

Shulamith Kreitler, PhD

Professor

School of Psychological Sciences

Tel-Aviv University

Tel-Aviv, Israel

Director

Psychooncology Research Center

Sheba Medical Center

Tel Hashomer, Israel

Elena Abigail Krivoy, MSc

Senior Clinical and Medical Psychologist

Department of Pediatric Hematology and Oncology

The Ruth Rappaport Children's Hospital

Rambam Health Care Campus

Haifa, Israel

Larry E. Kun, MD

Clinical Director
St Jude Children's Research Hospital
Chair
Department of Radiological Sciences
Memphis, Tennessee

Anne Laprie, MD, PhD

Assistant Professor
Department of Radiotherapy
Institut Universitaire du Cancer de Toulouse-Oncopole
Toulouse, France

Shannon M. MacDonald, MD

Associate Professor
Department of Radiation Oncology
Harvard Medical School
Radiation Oncologist
Department of Radiation Oncology
Massachusetts General Hospital
Boston, Massachusetts

Anita Mahajan, MD

Professor
Department of Radiation Oncology
Division of Radiation Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Monika Metzger, MD, MSc

Regional Director
South and Central American Regions
Member
Department of Oncology and Global Pediatric Medicine
St Jude Children's Research Hospital
Memphis, Tennessee

Brandon R. Mancini, MD

Chief Resident
Department of Therapeutic Radiology
Yale School of Medicine
Yale University
New Haven, Connecticut

Karen J. Marcus, MD

Associate Professor
Department of Radiation Oncology
Harvard Medical School
Division Chief
Division of Radiation Oncology
Boston Children's Hospital
Boston, Massachusetts

Katherine K. Matthay, MD

Mildred V. Strauss Professor of Translational Research in Childhood Cancer
Chief
Pediatric Hematology and Oncology Unit
Department of Pediatrics
Leader
Pediatric Malignancies Program
University of California
School of Medicine
UCSF Benioff Children's Hospital
San Francisco, California

Ronica H. Nanda, MD

Chief Resident
Department of Radiation Oncology
Winship Cancer Institute
Emory University
Atlanta, Georgia

Kenneth B. Roberts, MD

Professor
Department of Therapeutic Radiology
Yale School of Medicine

Yale University
Associate Chief
Department of Radiation Oncology
Yale-New Haven Hospital
New Haven, Connecticut

Scott R. Schulman, MD, MHSc

Professor
Department of Anesthesiology, Pediatrics and Surgery
Director
Department of Pediatric Cardiac Anesthesiology
Benioff Children's Hospital
University of California
San Francisco, California

Eric Yi-Liang Shen, MD

Attending Physician
Department of Radiation Oncology
Chang Gung Memorial Hospital
Linkou, Taiwan

Nancy J. Tarbell, MD, FASTRO

CC Wang Professor
Department of Radiation Oncology
Massachusetts General Hospital
Dean for Academic and Clinical Affairs
Harvard Medical School
Boston, Massachusetts

Stephanie A. Terezakis, MD

Associate Professor
Department of Radiation Oncology and Molecular Radiation Sciences
Johns Hopkins School of Medicine
Baltimore, Maryland

Amos Toren, MD, PhD, MHA

Professor
Director

Division of Pediatric Hemato-Oncology
The Edmond and Lily Safra Children's Hospital
Sheba Medical Center
Tel Hashomer
Tel-Aviv University
Tel-Aviv, Israel

Howard J. Weinstein, MD

Chief
Pediatric Hematology and Oncology Unit
Massachusetts General Hospital for Children
Professor of Pediatrics
Harvard Medical School
Boston, Massachusetts

Suzanne L. Wolden, MD, FACP

Member
Department of Radiation Oncology
Memorial Sloan Kettering Cancer Center
New York, New York
Tel-Aviv University
Hopkins Hospital
Baltimore, Maryland

Michal Yalon Oren, MD, PhD

Head of Pediatric Neuro-Oncology Service
Department of Pediatric Hemato-Oncology
Sheba Medical Center
Tel Hashomer, Israel

Torunn I. Yock, MD, MCH

Director
Department of Pediatric Radiation Oncology
Associate Professor
Harvard Medical School
Chair
Radiation Oncology Quality Assurance
Quality Improvement Chair

Francis H Burr Proton Therapy Center
Boston, Massachusetts

“Every child begins the world again.”

Henry David Thoreau

Evil spirits, the disharmony of celestial bodies, and the wrath of the gods were all invoked as etiologies for what we today recognize as *cancinos* or *carcinoma* (coined by Hippocrates). Ultimately, cancer was understood to be a myriad of diseases, but those afflicted were shut away to die if surgical approaches (and those for children were pioneered in the 19th century) failed. In the art of antiquity, children were often depicted as small versions of adults; similarly our treatment approaches were adapted from those suitable for adults. The vulnerability of children to the effects of our therapies required visibility before substantial progress could be made in curing without unacceptable harm. As radiation oncologists, we are fortunate to spend our lives striving to help patients with cancer, curing them when possible, and improving their quality of life when cure is beyond reach.

Marie Curie said: “*Nothing in life is to be feared. It is only to be understood.*” She could well have been alluding to the historic fears engendered by the mysterious force that was radiation, but this axiom surely embodies the progress we have made with these diseases. It was the compassion and passionate determination to cure children with cancer that permitted the metamorphosis from hopelessness to optimism in its treatment, and this required the unrelenting efforts of our professional predecessors.

In 1986, one of us (Edward C. Halperin) conceived the idea of a new textbook of pediatric radiation oncology. While several general textbooks in radiation oncology existed, none were specifically devoted to the use of radiation therapy in the treatment of childhood cancer. When Dr. Halperin first proposed such a book, most publishing companies rejected it on the grounds that the market was too small to sustain a book of this type. After several rejections, Raven Press of New York City had the foresight to agree. Dr. Halperin, at that time a 32-year-old assistant professor, invited and persuaded his colleague Larry E. Kun, at St. Jude Children’s Research Hospital in Memphis, Tennessee, to join him in the project. Drs. Kun and Halperin then drew up the outline for the proposed book and completed the team with Drs. Nancy J. Tarbell of Boston and Louis S. Constine of Rochester.

We had a very specific vision for this book. Most clinical radiation oncology textbooks

were massive tomes perfectly appropriate for propping a door open or lifting up the slide projector for the morning lecture. Our goal for *Pediatric Radiation Oncology* was considerably different because we wanted it to be manageable and engaging for young physicians who had little time for exhaustive investigation in order to understand and propose treatment for a new patient. We sought to write chapters that could be read in one sitting. We envisioned a resident-in-training, the night before morning teaching conference, needing a reliable book to turn to and read a chapter that would render him or her able to reasonably defend a rational treatment approach for their patient. Furthermore, when we first envisioned this book, it was well before the age of computer-augmented searches for journal articles or expert (and trusted) summary information. We intended to synthesize data on pathogenesis, pathology, diagnostic workup, staging, treatment approaches (particularly radiation therapy—indications, doses, volumes, treatment planning), and toxic outcomes. We also intended to provide rational judgment for decision making when data was lacking.

It is hard to believe that three decades have passed since Dr. Halperin's concept both germinated and blossomed into what will now be the sixth edition. Our founding principles remain steadfast. We have tried to compose all of the chapters with a common voice, avoiding repetition and maintaining uniformity of style. We have paid respect to historical information and have paid due deference to the many controversies in the field. The passage of time has allowed us to witness considerable evolution in pediatric radiation oncology. When we wrote the first edition of this book, the role of radiation therapy in the treatment of childhood leukemia, retinoblastoma, neuroblastoma, Hodgkin disease, Wilms tumor, and Langerhans histiocytosis were all vastly different than they are now. The information that we were able to present to our readers about the late effects of cancer treatment (including second malignant neoplasms) was also in its infancy.

The challenge of pediatric radiation oncology derives from the broad spectrum of complex diseases, all with their own biology and natural history. The optimal and creative integration of radiation therapy into their management requires a sophisticated understanding of the disease as well as the adverse consequences of all treatment modalities. Pediatric oncology scares many radiation oncologists because each new patient opens a foreign world into which the doctor must not only enter but be successful. The stakes are high since most childhood cancers are curable, but the child can be injured and live a long time with the injury.

We have all aged (gracefully and wisely, we hope) through these 30 years together, and through these editions. The reader will see evidence of the original authors having passed the torch to the new generation of pediatric radiation oncologists in the writing of these chapters. Passing the torch is an energy-requiring process since many radiation oncologists do not become experts in pediatrics since the patient numbers are small, obtaining expertise requires

a huge investment of time, and there is little personal financial reward in return for the investment.

The response to this book has been gratifying. We never imagined in 1986 that there would be six editions of this book and that it would have assumed a niche in the medical literature. Indeed, we have sat at medical meetings and heard this text referred to simply as “the book.”

We hope that all six editions of this book have contributed to an improved understanding of the benefits and risks of radiotherapy for children. We remain resolute in our belief that the dissemination of knowledge about pediatric radiation oncology will improve the quality and quantity of life for children afflicted with cancer. We hope that this book helps to demystify pediatric cancer and its treatment.

Louis S. Constine
Nancy J. Tarbell
Edward C. Halperin
January 2, 2016

Acknowledgments

The preparation and collation of the sixth edition of this book is grounded in the multiple previous editions that resulted from the dedication of the late Ruth Aultman in North Carolina and Kentucky, Rebecca Bunker in Memphis, Laura Finger in Rochester, Erin Cromack and Heidi Fliegauf in Boston, and Vera Rosario and Vilma Bordonaro in Valhalla. Emilie Moyer and the staff of Lippincott Williams & Wilkins were, at all times, courteous and beyond helpful. The conscientiousness and skill of this staff has again given life to our book.

We are indebted to our mentors and teachers: J. Robert Cassady, Juan A. del Regato, Sarah Donaldson, Samuel Hellman, Henry Kaplan, Rita M. Linggood, Jay Loeffler, Donald Pinkel, Leon Rosenberg, Philip Rubin, Herman Suit, Samuel Thier, and John Truman.

The love of our families has been a source of constant strength to us.

CHAPTER 1

The Cancer Problem in Children

Edward C. Halperin

In 1900, cancer trailed typhoid fever, malaria, smallpox, measles, scarlet fever, whooping cough, diphtheria, croup, influenza, dysentery, erysipelas, tuberculosis, sexually transmitted disease, meningitis, acute bronchitis, pneumonia, accidents, birth injuries, and violence as a cause of death in children in the United States (1,2). Cancer mortality constituted only 0.43% of mortality from all causes for children (1).

At the beginning of the 21st century, in economically developed countries, many children die every year from preventable incidents such as traffic accidents, intentional injuries, drowning, falls, fire, and poisoning. The leading causes of death in infants are congenital anomalies, disorders related to short gestation and low birth weight, and sudden infant death syndrome (3). The leading cause of death in children older than 1 year is murder by a close relative. Cancer in children, however, has become a significant problem compared with other causes of childhood mortality (4) (Table 1.1).


In the United States, 1 in 285 children will be diagnosed with cancer before age 20 (5). In 2014, there were 10,450 new cases of cancer among children of age 0–14 years and 5330 new cases among children of age 15–19 years in the United States (5,6,7). Cancer is

TABLE 1.1

The Five Leading Causes of Death in the United States in 2011 for 1- to 19-Year-Olds

Cause of Death	Number of Deaths
Accidents	7310
Homicide	2375
Suicide	2089
Cancer	1852
Congenital anomalies	1058

Data from Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. *CA Cancer J Clin.* 2015;65:5–29.

Table 1.1  The Five Leading Causes of Death in the United States in 2011 for 1- to 19-Year-Olds

now the leading natural cause of death among children between the ages of 1 and 14 years in the United States (3). In late adolescence, homicide surpasses cancer as a cause of death.

Although cancer is a major cause of childhood death in developed countries, it continues to trail infections as a cause of mortality in developing countries (6,8). In many parts of the world, nutrition, housing, climate, and sanitation conditions create childhood mortality statistics similar to those reported for industrialized countries in the early 20th century. However, it is likely that future improvements in the standard of living, the success of immunization programs, and dissemination of medical services will make inroads against infectious disease, and thereby make childhood cancer a major cause of death in developing nations.

Figure: The Five Leading Causes of Death in the United States in 2011 for 1- to 19-Year-Olds

TABLE 1.1**The Five Leading Causes of Death in the United States in 2011 for 1- to 19-Year-Olds**

Cause of Death	Number of Deaths
Accidents	7310
Homicide	2375
Suicide	2089
Cancer	1852
Congenital anomalies	1058

Data from Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015, *CA Cancer J Clin.* 2015;65:5–29.

RELATIVE FREQUENCY OF THE VARIOUS TYPES OF CHILDHOOD CANCER

Adults generally get cancer of places where their bodies interact with the environment; for the most part, children do not. Whereas adults often get cancer as a result of tobacco consumption, dietary habits, and sun exposure of the epithelial surfaces of the body, children get cancer as a result of intrinsically occurring mutations provoking oncogene and tumor suppressor gene activity or inactivity (Table 1.2).

The relative frequency of the various types of childhood cancer is influenced by whether we are examining incidence or mortality and by how we stratify by age, sex, or nationality. Among the most commonly used data are those of the Surveillance, Epidemiology, and End Results (SEER) program. SEER is a project of the Biometry Branch of the U.S. National Cancer Institute (NCI). The program draws data from several population-based cancer reporting systems covering approximately 10% of the total population of the United States (7,9) (Table 1.3). Leukemias, brain and spinal tumors, lymphomas, sympathetic nervous system tumors (neuroblastoma), kidney (Wilms) tumors, and soft tissue and bone sarcomas are the most common childhood cancers, whereas the common epithelial tumors of adults are rare in children. Cancers that arise from embryonic cells or in developing tissues and organ systems are characteristic of children and are rarely seen in adults. Examples of embryonal cancers are neuroblastoma, Wilms tumor or

TABLE 1.2

The Five Most Common Forms of Cancer in Adults in the United States Compared with the Five Most Common Forms of Cancer in Children

Adults	Children
1. Breast	1. Leukemia
2. Lung	2. Central nervous system
3. Prostate	3. Lymphoma
4. Colon	4. Malignant epithelial neoplasms such as adrenocortical carcinoma, thyroid carcinoma, nasopharyngeal carcinoma, and melanoma
5. Bladder	5. Soft tissue and other extraosseous sarcoma

Note: The childhood cancers are organized by the International Classification of Childhood Cancer Group (excluding basal and squamous cell skin cancer and *in situ* carcinoma except in urinary bladder). Data from SEER Cancer Statistics Review 1975–2010, Table 29.1, National Cancer Institute.

Table 1.2 The Five Most Common Forms of Cancer in Adults in the United States Compared with the Five Most Common Forms of Cancer in Children

nephroblastoma, medulloblastoma (brain), hepatoblastoma (liver), retinoblastoma (eye), and rhabdomyosarcoma (muscle) (5,10).

Page 2 Of the cancers that do afflict children, some are more common in specific age groups. For example, neuroblastomas are more common in infancy. The ratio of non-Hodgkin lymphoma to Hodgkin disease favors non-Hodgkin lymphoma in younger children, but the reverse is true in adolescents. There is a steep rise in bone cancers among children aged 11 through 15, which coincides with the adolescent growth spurt. The most common tumors of neonates (younger than 28 days of age) are teratomas, retinoblastoma, rhabdomyosarcoma, and neuroblastoma (11,12). In 15-to-19-year-olds, the most common forms of cancer are malignancies of the brain and central nervous system (20%), followed by leukemia (13%), Hodgkin lymphoma (13%), thyroid carcinoma (10%), gonadal germ cell tumors (9%), and melanoma (5%) (6).

In general, approximately one-third of childhood cancer deaths are caused by leukemia and about one-fifth of these deaths are caused by brain tumors (5,6,10,13,14) (Table 1.4). In 0-to-14-year-olds, U.S. cancer incidence and mortality rates are lower in girls, whereas in 15-to-19-year-olds, boys and girls have similar cancer incidence rates, with girls having lower mortality rates. This may be related to differences in the frequency of types of cancer in boys versus girls. Non-Hispanic white and Hispanic children have the highest cancer incidence rates. African American children have lower cancer survival rates (5).

About 175,000 cases of cancer are diagnosed annually in children <15 years of age worldwide. Less than 40% of these children are adequately diagnosed and treated (5). Childhood cancer incidence varies throughout the world. This may be related in part to fundamental issues of biology and demographics. It can also be related to the reporting system of a country and its level of economic development.

TABLE 1.3

The Incidence Rates of Cancer in the United States for 0- to 19-Year-Olds Expressed as a Percentage of the Total Number of Cancer Cases in This Age Group, 2006-2010

Diagnosis	Percentage of the Total
Leukemia	26
Central nervous system	24
Lymphoma	13
Other malignant epithelial neoplasms such as adrenocortical carcinoma, thyroid carcinoma, nasopharyngeal carcinoma, and melanoma	9
Soft tissue and other extraosseous sarcomas	6
Germ cell and other trophoblastic tumors and neoplasms of the gonads	6
Malignant bone tumors	5
Neuroblastoma and other peripheral nervous cell tumors	4
Renal tumors	3
Retinoblastoma	2
Hepatic tumors	1
Other and unspecified	<1

Data from Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. *CA Cancer J Clin*. 2015;65:5-29 and SEER Cancer Statistics Review 1975-2010, Table 29.1. National Cancer Institute.

Table 1.3 The Incidence Rates of Cancer in the United States for 0- to 19-Year-Olds Expressed as a Percentage of the Total Number of Cancer Cases in This Age Group, 2006-2010

For example, the distribution of childhood cancers in Uruguay is very similar to that of North America. Uruguay has a per capita income much higher than that of the rest of Latin America and the Caribbean (15). However, the frequency of malignant solid tumors in children in a report from Pakistan was distinctly different from that in the rest of the world (16). In Cuba, the most common childhood tumor is leukemia (31%), followed by lymphoma (18%), central nervous system (CNS) tumors (15%), sympathetic nervous system tumors (7%), soft tissue sarcomas (6%), and renal tumors (5%) (17). In Thailand, leukemias are most common (40%), followed by CNS tumors (14%), lymphoma (12%), bone tumors (4%), and soft tissue sarcomas (4%) (18). In Eastern Nigeria, lymphoma leads the list (19). Although the absolute frequency of certain tumors is reported to be higher in developing countries than in industrialized states, there is likely to be variation in reporting standards, diagnostic techniques, and histopathologic review (20,21).

TABLE 1.4

The Most Common Causes of Pediatric Cancer Death in the United States, 2007–2011, by Primary Cancer Site for Ages 0–19

Cause of Death	Percentage of All Pediatric Cancer Deaths
Leukemia	29
Brain and other nervous system	25
Bone and joint	8
Soft tissue	8
Non-Hodgkin lymphoma	4
Kidney and renal pelvis	4

Data from SEER Cancer Statistics Review 1975–2011, Section 28, National Cancer Institute.


Table 1.4  **The Most Common Causes of Pediatric Cancer Death in the United States, 2007–2011, by Primary Cancer Site for Ages 0–19**

Figure: The Five Most Common Forms of Cancer in Adults in the United States Compared with the Five Most Common Forms of Cancer in Children

TABLE 1.2**The Five Most Common Forms of Cancer in Adults in the United States Compared with the Five Most Common Forms of Cancer in Children**

Adults	Children
1. Breast	1. Leukemia
2. Lung	2. Central nervous system
3. Prostate	3. Lymphoma
4. Colon	4. Malignant epithelial neoplasms such as adrenocortical carcinoma, thyroid carcinoma, nasopharyngeal carcinoma, and melanoma
5. Bladder	5. Soft tissue and other extraosseous sarcoma

Note: The childhood cancers are organized by the International Classification of Childhood Cancer Group (excluding basal and squamous cell skin cancer and in situ carcinoma except in urinary bladder).

Data from SEER Cancer Statistics Review 1975–2010, Table 29.1, National Cancer Institute.

Figure: The Incidence Rates of Cancer in the United States for 0- to 19-Year-Olds Expressed as a Percentage of the Total Number of Cancer Cases in This Age Group, 2006-2010

TABLE 1.3

The Incidence Rates of Cancer in the United States for 0- to 19-Year-Olds Expressed as a Percentage of the Total Number of Cancer Cases in This Age Group, 2006–2010

Diagnosis	Percentage of the Total
Leukemia	26
Central nervous system	24
Lymphoma	13
Other malignant epithelial neoplasms such as adrenocortical carcinoma, thyroid carcinoma, nasopharyngeal carcinoma, and melanoma	9
Soft tissue and other extraosseous sarcomas	6
Germ cell and other trophoblastic tumors and neoplasms of the gonads	6
Malignant bone tumors	5
Neuroblastoma and other peripheral nervous cell tumors	4
Renal tumors	3
Retinoblastoma	2
Hepatic tumors	1
Other and unspecified	<1

Data from Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. *CA Cancer J Clin.* 2015;65:5–29 and SEER Cancer Statistics Review 1975–2010, Table 29.1, National Cancer Institute.

Figure: The Most Common Causes of Pediatric Cancer Death in the United States, 2007-2011, by Primary Cancer Site for Ages 0-19

TABLE 1.4**The Most Common Causes of Pediatric Cancer Death in the United States, 2007–2011, by Primary Cancer Site for Ages 0–19**

Cause of Death	Percentage of All Pediatric Cancer Deaths
Leukemia	29
Brain and other nervous system	25
Bone and joint	8
Soft tissue	8
Non-Hodgkin lymphoma	4
Kidney and renal pelvis	4

Data from SEER Cancer Statistics Review 1975–2011, Section 28, National Cancer Institute.

TRENDS IN CHILDHOOD CANCER MORTALITY RATES

The mortality rate from childhood cancer has fallen dramatically in the United States. Particularly impressive gains have been posted for acute lymphocytic leukemia (ALL), bone tumors (predominantly osteosarcoma and Ewing sarcoma), Hodgkin disease, non-Hodgkin lymphoma, soft tissue sarcomas (including rhabdomyosarcoma and nonrhabdomyosarcoma soft tissue sarcomas), and Wilms tumor. Although gains have also been achieved for acute myelocytic leukemia (AML), neuroblastoma, and brain tumors, the improvements have been less dramatic or confined to certain subgroups or stages (Table 1.5). In general, however, the diagnosis and treatment of childhood cancer has been one of the success stories of modern medicine.

TABLE 1.5

Trends in 5-Year Relative Survival Rates for Children with Cancer (0–14 Years of Age) in the United States at the Approximate Midpoint of the Last Four Decades

Diagnosis	1975–1977 (%)	1984–1986 (%)	1993–1995 (%)	2004–2010 (%)
All sites	58	68	77	83
Acute lymphocytic leukemia	57	72	84	92
Acute myeloid leukemia	19	31	41	66
Bone and joints	50	57	74	79
Brain and other nervous system	57	62	71	74
Hodgkin lymphoma	81	90	95	98
Neuroblastoma	53	52	67	77
Non-Hodgkin lymphoma	43	70	81	86
Wilms tumor	73	91	92	92

Data from Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. *CA Cancer J Clin*. 2015;65:5–29.

Table 1.5 Trends in 5-Year Relative Survival Rates for Children with Cancer (0–14 Years of Age) in the United States at the Approximate Midpoint of the Last Four Decades

An estimated 1350 cancer deaths in children 0–14 years of age and 610 cancer deaths in 15-to-19-year-olds occurred in the United States in 2014. It is clear that when compared with adult cancer, childhood cancer is a vanishingly rare event. For example, in 2015 there were

158,000 estimated deaths from lung cancer alone in the United States (6). The comparative infrequency of childhood cancer is highlighted by the fact that more people in the United States die of lung cancer in 1 week than children die of all forms of cancer in 1 year. Looking at the impact of cancer solely in this manner is insufficient. If one looks at a death from cancer in terms of potential years of life lost, then the death of an 8-year-old from ALL has a greater statistical weight than the death of an 82-year-old from small cell carcinoma of the lung. Therefore, the success of medical treatment of childhood cancer has a significant public health impact when considered in terms of the person-years of potential life lost or lifetime earnings saved. A lifetime is saved for every child cured of cancer.

Figure: Trends in 5-Year Relative Survival Rates for Children with Cancer (0-14 Years of Age) in the United States at the Approximate Midpoint of the Last Four Decades

TABLE 1.5**Trends in 5-Year Relative Survival Rates for Children with Cancer (0–14 Years of Age) in the United States at the Approximate Midpoint of the Last Four Decades**

Diagnosis	1975–1977 (%)	1984–1986 (%)	1993–1995 (%)	2004–2010 (%)
All sites	58	68	77	83
Acute lymphocytic leukemia	57	72	84	92
Acute myeloid leukemia	19	31	41	66
Bone and joints	50	57	74	79
Brain and other nervous system	57	62	71	74
Hodgkin lymphoma	81	90	95	98
Neuroblastoma	53	52	67	77
Non-Hodgkin lymphoma	43	70	81	86
Wilms tumor	73	91	92	92

Data from Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. *CA Cancer J Clin*. 2015;65:5–29.

FUNDING OF PEDIATRIC CANCER RESEARCH

In the United States, there is a significant federally funded pediatric cancer research program. Research focuses on treatment in cancer biology and the management of long-term cancer survivors (Table 1.6). We know very little about pediatric cancer prevention in contrast to the extensive efforts in tobacco and alcohol consumption control, reduction in sun exposure, and dietary interventions promoted to reduce adult cancer. Unfortunately, the amount of U.S. federal inflation-adjusted dollars spent on pediatric cancer research has fallen in recent years (Table 1.7).

TABLE 1.6

Percentage of Total Dollars Spent by Scientific Area in Pediatric Cancer Research by the United States National Cancer Institute for Fiscal Year 2013

Scientific Area	Percentage of Total Expenditures
Treatment	44
Biology	17
Cancer control, survivorship, and outcomes research	15
Etiology	10
Early detection, diagnosis, and prognosis	7
Scientific model systems	5
Prevention	2


From National Cancer Institute. A snapshot of pediatric cancers.
<http://www.cancer.gov/research/progress/snapshots/pediatric>.

Table 1.6 Percentage of Total Dollars Spent by Scientific Area in Pediatric Cancer Research by the United States National Cancer Institute for Fiscal Year 2013

TABLE 1.7**The Yearly Investment of the United States National Cancer Institute in Pediatric Cancer Research**

Year	Funding in Millions of US Dollars Not Adjusted for Inflation
2009	192.8
2010	197.1
2011	195.5
2012	208.1
2013	185.1

Data from National Cancer Institute. A snapshot of pediatric cancers.
<http://www.cancer.gov/research/progress/snapshots/pediatric>.

Table 1.7  **The Yearly Investment of the United States National Cancer Institute in Pediatric Cancer Research**